Associated tags: Leukemia & Lymphoma Society, Patient, LLS, Leukemia, Bone marrow, MYB, Protein, Pharmaceutical industry, Acceleration, Lymphoid leukemia, Safety, Rituximab, Follicular lymphoma, Disease, ClinicalTrials.gov, Maintenance, Inflammation, RNA, Lenalidomide, CSO
Retrieved on:
Tuesday, January 30, 2024
Partnership,
MYB,
RNA,
Oncogene,
Therapy,
Leukemia & Lymphoma Society,
Patient,
LLS,
Leukemia,
Bone marrow,
TAP,
CSO CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.
Key Points:
- CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.
- "We are honored by the support and recognition of LLS's Therapy Acceleration Program.
- LLS's strategic investment in Rgenta continues to bolster our confidence in the potential of our pipeline of oral, small-molecule RNA-targeting medicines," commented Simon Xi, Ph.D., CEO of Rgenta.
- "We look forward to tapping into the extensive clinical expertise and resources from LLS to accelerate the development of our RNA-targeting MYB inhibitor molecules."
Leukemia,
Lenalidomide,
ClinicalTrials.gov,
Inflammation,
Maintenance,
Protein,
LLS,
Disease,
Follicular lymphoma,
Rituximab,
Leukemia & Lymphoma Society,
Bone marrow,
Safety,
Lymphoid leukemia,
Patient,
Acceleration,
Pharmaceutical industry,
Vaccine PARIS, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that it received a €3 million investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP). The funding will propel the Company’s ongoing Phase 2 SIDNEY study of EO2463 in indolent non-Hodgkin B-cell lymphoma (iNHL).
Key Points:
- PARIS, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that it received a €3 million investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP).
- The funding will propel the Company’s ongoing Phase 2 SIDNEY study of EO2463 in indolent non-Hodgkin B-cell lymphoma (iNHL).
- Moreover, it could provide a key building block for the next generation of combination and maintenance therapies.”
“We are honored to be recognized and supported by LLS’s Therapy Acceleration Program,” said Dr. Pierre Belichard, Chief Executive Officer of Enterome.
- The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL).
